New Version of Gardasil Doubles Aluminum Content

Recently, the FDA approved a ‘new and improved’ version of Gardasil dubbed Gardasil 9 in which the amount of aluminum is more than double than in the original formulation. With that being said, Gardasil 9 also was approved without being consulted by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) that ‘is responsible for reviewing and evaluating data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products.’

During the approval, a signed FDA letter by Marion Gruber who is the Director of Office of Vaccines Research and Review, stated that Gardasil 9 ‘did not raise concerns or controversial issues,’ thus was approved without examination by VRBPAC. The controversial issue at hand is that this new formula was approved with more than double the amount of aluminum content while there are numerous reports and data from adverse health effects related to the original formula.

With that being said, David A. Geier and Mark R. Geier, a father-son research team, published a study just two days before Gardasil 9 was approved, that found thousands instances of adverse events documented that was related to the original formula. In their study, they examined data from the Vaccine Adverse Event Reporting System (VAERS) with dates ranging from January 2006 to December 2012. Upon reviewing the database, they were pinpointing autoimmune adverse events (SAAEs) in women between the ages of 18 to 39 years old.

The two researchers analyzed the data and found 22,011 adverse events in the VAERS database from women who were administered Gardasil. These women suffered the following SAAEs:

  • Guillain-Barre Syndrome
  • Gastroenteritis
  • Systemic Lupus Erythematosus,
  • Arthritis
  • Vasculitis
  • Alopecia
  • Central Nervous System Conditions

They suggest that there is significant evidence of a causal relationship between Gardasil and the resulting SAAEs. Not only does their study document many adverse events following the administration of Gardasil, but other CMSRI funded researchers have published reports of similar findings in which women experience adverse reactions after receiving doses of Gardasil and some reactions have resulted in deaths. This new study highlights the strong links between this vaccine and certain autoimmune adverse reactions which previously have been linked to neurotoxic aluminum used in Gardasil. Doubling the amount of aluminum without conducting further research on how it may affect the already significant rate of adverse reactions is fraud and negligence on behalf of health agencies responsible for ensuring the safety of the vaccines recommended, and in some cases, mandated for use.

Other studies have dismissed the increase in reported autoimmune reactions after Gardasil, claiming their appearance after receiving the vaccine is only a “coincidence.” In that case, there has been an epidemic increase of “coincidence” since Gardasil has been approved, especially “severe coincidences.”

As Gardasil 9 is released and marketed as the “new and improved” version of Gardasil, health-conscious consumers should take note of the additional toxic ingredients in the formula, which includes more than double the amount of aluminum adjuvant that has already demonstrated harm at lower levels, as well as other potentially harmful ingredients.

Based on the results of this and several other independent studies, Gardasil has demonstrated risks that exceed the benefits, and this should make parents think twice about the new vaccine which contains more than double the amount of aluminum.


Read More

Children At Risk: Aluminum Adjuvants

With over 80 years of use, the safety of aluminum adjuvants used in vaccines continues to rest on assumptions rather than scientific evidence. To date, a minimal amount of scientific evidence or research has been conducted regarding the safety of vaccines and the ingredients that come with them. That being said, recent research has shown pediatric populations suffer from unknown adverse reactions that stem from the toxicity of aluminum adjuvants.

Evidence that is available draws the conclusion that long-term persistence of aluminum adjuvants in adults can lead to cognitive dysfunction and autoimmunity. This raises the question – how does its use affect developing children? Since children and adults receive the same vaccines with the same dosage, children continue to be regularly exposed to much higher levels of aluminum adjuvants than adults because of their smaller and unique body structure.

Christopher Shaw and Lucija Tomljenovic are funded researchers of Children’s Medical Safety Research Institute and have drawn concerns regarding the use of neurotoxic substances such as aluminum as an adjuvant in pediatric vaccine formulations. The researchers urge that infants and young children should not be considered “small adults” when it comes to toxicological risks. The use of the same vaccinations should cease because children are not fully developed. The inherent risks pose developmental concerns when injecting the aluminum adjuvants because it can manipulate the autoimmune system in negative ways.

They suggest that aluminum vaccines cause multifactorial stimulatory effects on the immune system that can result in antigenic compounds failure to launch adequate immune responses. Also, during prenatal and early postnatal development, the brain is extremely vulnerable to neurotoxic insults. The development is highly sensitive and exposure to the neurotoxins will have a permeable impact to vital living functions. In addition to the early developmental stages of children and infants, ‘the immature renal system of the neonates significantly compromises their ability to eliminate environmental toxicants.’

This research should be enough evidence that children are at a higher risk of adverse reactions from aluminum adjuvants than adults. Infants and children have a unique physiology compared to adults that makes them much more vulnerable to noxious environmental insults.

Read More